Kura Oncology, Inc. (NASDAQ:KURA) Q4 2022 Earnings Conference Call February 23, 2023 4:30 PM ET

Company Participants

Pete De Spain - Senior Vice President of Investor Relations and Corporate Communications

Troy Wilson - President and Chief Executive Officer

Tom Doyle - Senior Vice President of Finance and Accounting

Conference Call Participants

Jonathan Chang - SVB Securities

Roger Song - Jefferies Group LLC

Peter Lawson - Barclays

Li Watsek - Cantor Fitzgerald, L.P.

Bradley Canino - Stifel Financial Corp.

Eva Privitera - Cowen Inc.

Reni Benjamin - JMP Securities LLC

Operator

Greetings, and welcome to Kura Oncology’s Fourth Quarter 2022 Earnings Conference Call. At this time, all participants are in a listen-only mode. A question-and-answer session will follow the formal presentation. [Operator Instructions] As a reminder, this conference is being recorded.

I would now like to turn the conference over to your host, Mr. Pete De Spain. Thank you. You may begin.

Pete De Spain

Thank you, Rob. Good afternoon and welcome to Kura Oncology’s fourth quarter and full year 2022 conference call. Joining me on the call are Dr. Troy Wilson, our President and Chief Executive Officer; and Tom Doyle, our Senior Vice President of Finance and Accounting. Dr. Stephen Dale, our Chief Medical Officer is also with us and available to answer questions.

Before I turn the call over to Dr. Wilson, I’d like to remind you that today’s call will include forward-looking statements based on current expectations. Such statements represent management’s judgment as of today, and may involve risks and uncertainties that could cause actual results to differ materially from expected results. Please refer to Kura’s filings with the SEC, which are available from the SEC or on the Kura Oncology website for information concerning risk factors that could affect the company.

With that, I’ll now turn the call over to Troy.

Troy Wilson

Thank you, Pete, and thank you all for joining us. Let’s jump right in. In December, we were proud to report updated data from our Phase 1 trial of ziftomenib at the American Society of Hematology Annual Meeting. ziftomenib is our once-daily oral drug candidates targeting the menin-KMT2A protein-protein interaction for the treatment of genetically defined AML patients with high unmet need. The data at ASH highlighted the encouraging safety profile and clinical activity of ziftomenib in patients with relapsed/refractory AML.

Notably, the data included a 30% complete response rate with full count recovery among 20 patients with NPM1-mutant AML treated at the 600 milligram dose. To our knowledge, this represents one of the highest response rates reported to date for targeted therapies in a relapsed/refractory setting. A median duration of response had not been reached as of the ASH data cutoff on October 24.